Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review)

International Journal of Oncology

Volumn 37, Issue 3, 2010, Pages 533-539

  Wang, Long G ^a   Chiao, J W ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Epigenetics; Histone acetylation; Phenethyl isothiocyanate; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; DNA METHYLTRANSFERASE 1; GLUTATHIONE TRANSFERASE; PHENETHYL ISOTHIOCYANATE; PROTEIN P21; PROTEIN P27;

ANTINEOPLASTIC ACTIVITY; BRASSICA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; CPG ISLAND; DEMETHYLATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME REACTIVATION; EPIGENETICS; GENE CONTROL; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; METHYLATION; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DOWN REGULATION; REVIEW; VEGETABLE;

ANIMALS; ANTICARCINOGENIC AGENTS; EPIGENESIS, GENETIC; HUMANS; ISOTHIOCYANATES; MALE; PROSTATIC NEOPLASMS;

EID: 77956544792     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000702     Document Type: Review

References (65)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 50: 225-249, 2009.
2. Sakr WA, Haas GP, Cassin BF, Pontes JE and Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379-385, 1993. (Pubitemid 23215874)
3. Lieberman R, Bermejo C, Akaza H, Greenwald P, Fair W and Thompson I: Progress in prostate cancer chemoprevention: modulators of promotion and progression. Urology 58: 835-842, 2001. (Pubitemid 34017253)
4. Cohen LA: Nutrition and prostate cancer: a review. Ann NY Acad Sci 963: 148-155, 2002.
5. Muir CS, Nectoux J and Staszewski J: The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 30: 133-140, 1991.
6. Belinsky SA, Klinge DM, Stidley CA, et al: Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63: 7089-7093, 2003.
7. Graham S, Haughey B, Marshall J, et al: Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 70: 687-692, 1983.
8. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE and Mack TM: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63: 963-966, 1991.
9. Kristal AR and Lampe JW: Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer 42: 1-9, 2002. (Pubitemid 35007000)
10. Cohen JH, Kristal AR and Stanford JL: Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92: 61-68, 2000.
11. Kolonel LN, Hankin JH, Whittemore AS, et al: Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 9: 795-804, 2000.
12. Fenwick GR, Heaney RK and Mullin WJ: Glucosinolates and their breakdown products in food and food plants. Crit Rev Food Sci Nutr 18: 123-201, 1983.
13. Sones HR and Fenwick GR: An estimate of the mean daily intake of glucosinolate from cruciferous vegetables in the UK. J Sci Food Agr 35: 712-715, 1984.
14. Chung FL, Morse MA, Eklind KI and Lewis J: Quantitation of human uptake of the anticarcinogen phenethyl isothiocyanate after a watercress meal. Cancer Epidemiol Biomarkers Prev 1: 383-388, 1992.
15. Hecht SS: Chemoprevention by isothiocyanates. J Cell Biochem Suppl 22: 195-209, 1995.
16. Khor TO, Cheung WK, Prawan A, Reddy BS and Kong AN: Chemoprevention of familial adenomatous polyposis in Apc (Min/+) mice by phenethyl isothiocyanate (PEITC). Mol Carcinog 47: 321-325, 2008.
17. Moy KA, Yuan JM, Chung FL, et al: Urinary total isothiocyanates and colorectal cancer: a prospective study of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17: 1354-1359, 2008.
18. Chiao JW, Chung F, Krzeminski J, et al: Modulation of growth of human prostate cancer cells by the N-acetylcysteine conjugate of phenethyl isothiocyanate. Int J Oncol 16: 1215-1219, 2000.
19. Kinoshita H, Shi Y, Sandefur C, et al: Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60: 3623-3630, 2000.
20. Nakayama T, Watanabe M, Suzuki H, et al: Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 80: 1789-1796, 2000.
21. Taplin ME and Balk SP: Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483-490, 2004.
22. Santos AF, Huang H and Tindall DJ: The androgen receptor: a potential target for therapy of prostate cancer. Steroids 69: 79-85, 2004. (Pubitemid 38315080)
23. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004.
24. Gao M, Ossowski L and Ferrari AC: Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 179: 336-346, 1999. (Pubitemid 29203158)
25. WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 61: 7544-7551, 2001.
26. Wang LG, Johnson EM, Kinoshita Y, et al: Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex. Cancer Res 68: 2678-2688, 2008.
27. Wang LG, Ossowski L and Ferrari AC: Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23: 5175-5184, 2004.
28. Marrocco DL, Tilley WD, Bianco-Miotto T, et al: Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 6: 51-60, 2007.
29. Chen L, Meng S, Wang H, et al: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4: 1311-1319, 2005.
30. Toft DO: Recent advances in the study of hsp90 structure and mechanism of action. Trends Endocrinol Metab 9: 238-243, 1998. (Pubitemid 28357615)
31. Cardozo CP, Michaud C, Ost MC, et al: C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch Biochem Biophys 410: 134-140, 2003.
32. Myzak MC, Karplus PA, Chung FL and Dashwood RH: A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64: 5767-5774, 2004.
33. Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J and Chiao JW: Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 46: 24-31, 2007.
34. Wang LG, Liu XM, Fang Y, et al: De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33: 375-380, 2008.
35. Wang LG, Liu XM and Chiao JW: Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis 27: 2124-2132, 2006. (Pubitemid 44530587)
36. Nakagawa H, Nuovo GJ, Zervos EE, et al: Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 61: 6991-6995, 2001.
37. Palmisano WA, Divine KK, Saccomanno G, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000.
38. Singal R, van Wert J and Bashambu M: Cytosine methylation repress glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res 61: 4820-4826, 2001.
39. Costello JF and Plass C: Methylation matters. J Med Genet 38: 285-303, 2001.
40. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440, 2002.
41. Kopelovich L, Crowell JA and Fay JR: The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 95: 1747-1757, 2003.
42. Pompeia C, Hodge DR, Plass C, et al: Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 64: 3465-3473, 2004.
43. Brooks JD, Paton VG and Vidanes G: Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev 10: 949-954, 2001. (Pubitemid 32844902)
44. Lee WH, Morton RA, Epstein JI, et al: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91: 11733-11737, 1994.
45. Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8: 514-519, 2002.
46. Woodson K, Gillespie J, Hanson J, et al: Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate 60: 25-31, 2004.
47. Liu XM, Jiang JD, Ferrari AC, Budman DR and Wang LG: Unique induction of p21(WAF1/CIP1) expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer 89: 1566-1573, 2003.
48. Fei P, Matwyshyn GA, Rushmore TH and Kong AN: Transcription regulation of rat glutathione S-transferase Ya subunit gene expression by chemopreventive agents. Pharm Res 13: 1043-1048, 1996. (Pubitemid 26259004)
49. Seo KW, Kim JG, Park M, Kim TW and Kim HJ: Effects of phenethyl isothiocyanate on the expression of glutathione S-transferases and hepatotoxicity induced by acetaminophen. Xenobiotica 30: 535-545, 2000.
50. Goessl C, Krause H, Muller M, et al: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 60: 5941-5945, 2000.
51. Yamada H, Vijayachandra K, Penner C and Glick A: Increased sensitivity of transforming growth factor (TGF) beta 1 null cells to alkylating agents reveals a novel link between TGFbeta signaling and O(6)-methylguanine methyltransferase promoter hypermethylation. J Biol Chem 276: 19052-19058, 2001.
52. Biniszkiewicz D, Gribnau J, Ramsahoye B, et al: Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality. Mol Cell Biol 22: 2124-2135, 2002.
53. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ and Day ML: Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66: 385-392, 2006. (Pubitemid 43166046)
54. Beklemisheva AA, Feng J, Yeh YA, Wang LG and Chiao JW: Modulating testosterone stimulated prostate growth by phenethyl isothiocyanate via Sp1 and androgen receptor down-regulation. Prostate 67: 863-870, 2007.
55. Craft N, Chhor C, Tran C, et al: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59: 5030-5036, 1999.
56. Agus DB, Cordon-Cardo C, Fox W, et al: Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91: 1869-1876, 1999.
57. Rohlff C, Blagosklonny MV, Kyle E, et al: Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate 37: 51-59, 1998.
58. Davies TG, Bentley J, Arris CE, et al: Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 9: 745-749, 2002.
59. Bakshi S, Bergman M, Dovrat S and Grossman S: Unique natural antioxidants (NAOs) and derived purified components inhibit cell cycle progression by downregulation of ppRb and E2F in human PC3 prostate cancer cells. FEBS Lett 573: 31-37, 2004. (Pubitemid 39141031)
60. Wang L, Liu D, Ahmed T, Chung FL, Conaway C and Chiao JW: Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol 24: 187-192, 2004.
61. Chiao JW, Wu H, Ramaswamy G, et al: Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis 25: 1403-1408, 2004.
62. Zhang Y and Talalay P: Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res 54 (Suppl 7): 1976-1981, 1994.
63. Mi L, Siao Z, Hood BL, et al: Covalent binding to tubulin by isothiocyanates: a mechanism of cell growth arrest and apopotosis. J Biol Chem 283: 22136-22146, 2008.
64. Kelly WK, O'Connor OA and Marks PA: Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11: 1695-1713, 2002. (Pubitemid 35469917)
65. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.